# Fruquintinib as a Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer

> **NCT04296019** · PHASE2 · UNKNOWN · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 110 (estimated)

## Conditions studied

- Colo-rectal Cancer

## Interventions

- **DRUG:** Fruquintinib

## Key facts

- **NCT ID:** NCT04296019
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-02-01
- **Primary completion:** 2023-07-01
- **Final completion:** 2025-01-01
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2021-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04296019

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04296019, "Fruquintinib as a Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04296019. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*